Whitney Ijem

Stock Analyst at Canaccord Genuity

(1.07)
# 2124
Out of 5,386 analysts
112
Total ratings
Success rate
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
VERV Verve Therapeutics
Downgrades: Hold
39 13
11.3 15.04% 6 Jun 17, 2025
TSHA Taysha Gene Therapie...
Maintains: Strong Buy
9 11
2.4 358.33% 10 Jun 3, 2025
RCKT Rocket Pharmaceutica...
Maintains: Buy
34 11
2.52 336.51% 8 Jun 3, 2025
NTLA Intellia Therapeutic...
Maintains: Buy
74 54
9.56 464.85% 6 Jun 3, 2025
PVLA Palvella Therapeutic...
Maintains: Buy
53 52
22.02 136.15% 3 May 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
68 66
13.29 396.61% 6 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
28 11
8.16 34.8% 6 Apr 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
81 92
62.59 46.99% 7 Apr 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
385 390
322.64 20.88% 8 Mar 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
9 9
n/a n/a 2 Mar 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
18 6
0.63 852.38% 6 Mar 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
121 136
36.51 272.5% 8 Feb 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Hold
408 424
441.18 -3.89% 8 Feb 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
13 13
n/a n/a 6 Nov 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
148 150
17.1 777.19% 3 Nov 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
93 84
55.12 52.39% 8 Oct 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
6 30
n/a n/a 2 Jul 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
260
n/a n/a 1 Feb 7, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Jan 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
120 240
4.36 5404.59% 4 Jul 23, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
33 0
n/a n/a 2 Feb 26, 2018